Summary
This is a Phase 1/2, open-label, multicenter, non-randomized study to investigate the safety,
tolerability, and clinical activity of HER2-specific dual-switch CAR-T cells, BPX-603,
administered with rimiducid to subjects with previously treated, locally advanced or
metastatic solid tumors which are HER2 amplified/overexpressed.